Seattle Genetics partners SGN-35 with Takeda

Seattle Genetics Inc. (NASDAQ:SGEN) partnered with Millennium Pharmaceuticals Inc. to co-develop Seattle Genetics' brentuximab vedotin ( SGN-35). The antibody-drug conjugate (ADC) composed of an anti-...